"Castration resistant prostate cancer" trang 1 - tải miễn phí từ tailieuXANH
Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: A multi-center analysis

Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: A multi-center analysis
8    69    0
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An Italian multicenter “real life” study

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An Italian multicenter “real life” study
8    69    2
Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis

Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
7    45    0
Demethylation of the miR-146a promoter by 5-Aza-2’-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer

Demethylation of the miR-146a promoter by 5-Aza-2’-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer
11    39    0
Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer
10    53    3
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: Results from a prospective observational study (CAPRO)

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: Results from a prospective observational study (CAPRO)
10    69    0
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: Study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: Study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
7    53    0
Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2 ) in patients with castration-resistant prostate cancer: Results of a Japanese post-marketing surveillance study

Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2 ) in patients with castration-resistant prostate cancer: Results of a Japanese post-marketing surveillance study
11    101    0
Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
6    81    0
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
10    53    0
Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer

Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer
9    69    0
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use programme in France

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use programme in France
9    80    0
Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand1 staining: A retrospective study

Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand1 staining: A retrospective study
11    51    1
Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
10    20    1
Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer

Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer
9    19    1
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report
7    78    0
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients

The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients
7    61    0
High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients

High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients
7    59    0
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study

The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study
10    53    0
Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling

Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling
12    59    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.